...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Additional Exempt Distribution- 2023-04-28

1) USA,  $1,900,920.00  

(2,333,335 common shares@ $0.81 CAN) + ( 2 warrants @ $0.81 expire 2028-04-28)

2) Alberta,  Promissory Note of $410,959.00 + ( 550,000 warrants @ $1.02 expire 2028-04-26)
 
Total: $2.311.879.00 (CAN)
Share
New Message
Please login to post a reply